Please assess the completion status of the following clinical trial:

Trial Title: Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of multiple myeloma (MM) meeting all of the following criteria:~  * Relapsed or refractory disease~ * Previously received ≥ 2 courses of antimyeloma treatment~* Measurable levels of myeloma paraprotein in serum (\> 0.5 g/dL) or urine (\> 0.2 g/24-hour urine collection) OR serum-free light-chain disease~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Absolute neutrophil count ≥ 1,000/mm\^3~* Platelet count ≥ 75,000/mm\^3~* Creatinine ≤ 2.5 mg/dL~* Bilirubin ≤ 2.0 mg/dL~* AST and ALT ≤ 3 times upper limit of normal~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use 2 methods of highly effective contraception ≥ 4 weeks before, during, and for 4 weeks after completion of study therapy~* No other malignancy within the past 5 years except treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast~* No serious medical condition, laboratory abnormality, or psychiatric illness that would preclude study treatment or put patient at unacceptable risk~* No known hypersensitivity to thalidomide or lenalidomide~  * No development of erythema nodosum in the presence of a reaction characterized by a desquamating rash while taking thalidomide or similar drugs~* No known hypersensitivity to any component of the pneumococcal polyvalent vaccine, including diphtheria toxin or CRM 197~* No known HIV positivity~* No infectious hepatitis type A, B, or C~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No more than 3 prior treatment regimens for MM~* More than 6 months since prior lenalidomide~* More than 28 days since prior experimental drug or therapy~* More than 1 month since prior systemic antimyeloma therapy~* More than 1 month since prior and no concurrent systemic corticosteroids~* No other concurrent anticancer agents or treatments or investigational agents~* No concurrent thalidomide~* No concurrent radiotherapy~* No other concurrent immune therapy or immunomodulatory agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
- Group 2 (Type: EXPERIMENTAL): Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).

Based on this trial design, predict the completion outcome and termination type (if applicable).